| |
| |
|
| Insider
Information: |
Fust Matthew K |
| Relationship: |
Director |
| City: |
Palo Alto |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
351,844 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$8,176,359 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
351,844 |
|
|
| Total
Value |
$8,176,359 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
1
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -16.2%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Jazz Pharmaceuticals Inc |
JAZZ |
EVP, Chief Financial O... |
2008-11-28 |
58,948 |
|
0 |
Premium* |
|
|
Onyx Pharmaceuticals Inc |
ONXX |
EVP & Chief Financial ... |
2013-10-01 |
0 |
2009-01-05 |
0 |
Premium* |
|
|
Ultragenyx Pharmaceutical Inc |
RARE |
|
2024-03-07 |
14,860 |
2014-01-30 |
0 |
Premium* |
|
|
Macrogenics Inc |
MGNX |
Director |
2019-02-06 |
500 |
|
0 |
Premium* |
|
|
Atara Biotherapeutics, Inc. |
ATRA |
|
2024-03-31 |
259,000 |
2015-05-15 |
0 |
Premium* |
|
|
Crinetics Pharmaceuticals, Inc. |
CRNX |
Director |
2024-03-20 |
18,536 |
2019-12-16 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
96 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 4 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| RARE |
Ultragenyx Pharmaceutical... |
Director |
– • – |
2022-03-04 |
4 |
OE |
$40.37 |
$302,775 |
D/D |
7,500 |
23,195 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
EVP & Chief Financial Officer |
• – – |
2013-08-08 |
4 |
AS |
$128.21 |
$319,499 |
D/D |
(2,492) |
40,303 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
EVP & Chief Financial Officer |
• – – |
2013-04-01 |
4 |
AS |
$86.13 |
$332,575 |
D/D |
(3,861) |
51,551 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
EVP & Chief Financial Officer |
• – – |
2013-02-28 |
4 |
OE |
$34.48 |
$344,800 |
D/D |
10,000 |
60,201 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
EVP & Chief Financial Officer |
• – – |
2013-05-13 |
4 |
OE |
$34.48 |
$354,075 |
D/D |
10,269 |
60,473 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
Chief Financial Officer |
• – – |
2012-07-25 |
4 |
AS |
$73.97 |
$385,171 |
D/D |
(5,207) |
67,924 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
Director |
– • – |
2020-07-01 |
4 |
AS |
$85.00 |
$425,000 |
D/D |
(5,000) |
13,550 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
Director |
– • – |
2018-05-30 |
4 |
AS |
$72.00 |
$454,969 |
D/D |
(6,319) |
8,750 |
0 |
- |
|
| ATRA |
Atara Biotherapeutics, In... |
Director |
– • – |
2018-05-14 |
4 |
S |
$43.57 |
$535,301 |
D/D |
(12,286) |
19,820 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
Director |
– • – |
2020-07-06 |
4 |
AS |
$90.00 |
$556,290 |
D/D |
(6,181) |
13,550 |
0 |
% |
|
| ONXX |
Onyx Pharmaceuticals Inc |
Chief Financial Officer |
• – – |
2012-08-06 |
4 |
OE |
$34.48 |
$603,124 |
D/D |
17,492 |
85,416 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
|
– • – |
2024-03-07 |
4 |
S |
$50.85 |
$620,443 |
D/D |
(12,195) |
14,860 |
0 |
% |
|
| ONXX |
Onyx Pharmaceuticals Inc |
EVP & Chief Financial Officer |
• – – |
2013-07-26 |
4 |
AS |
$130.50 |
$788,612 |
D/D |
(6,043) |
42,795 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
EVP & Chief Financial Officer |
• – – |
2013-01-10 |
4 |
AS |
$84.41 |
$865,582 |
D/D |
(10,199) |
50,201 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
EVP & Chief Financial Officer |
• – – |
2013-05-13 |
4 |
AS |
$97.54 |
$1,008,598 |
D/D |
(10,269) |
50,204 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
EVP & Chief Financial Officer |
• – – |
2013-10-01 |
4 |
D |
$125.00 |
$1,144,125 |
D/D |
(9,153) |
31,150 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
EVP & Chief Financial Officer |
• – – |
2013-02-28 |
4 |
AS |
$77.12 |
$1,156,800 |
D/D |
(15,000) |
45,201 |
0 |
- |
|
| CRNX |
Crinetics Pharmaceuticals... |
Director |
– • – |
2024-03-20 |
4 |
OE |
$18.29 |
$1,254,975 |
D/D |
60,000 |
36,036 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
Chief Financial Officer |
• – – |
2012-08-06 |
4 |
S |
$71.63 |
$1,578,267 |
D/D |
(22,009) |
63,407 |
0 |
- |
|
| CRNX |
Crinetics Pharmaceuticals... |
Director |
– • – |
2024-03-20 |
4 |
AS |
$43.57 |
$2,648,150 |
D/D |
(60,000) |
18,536 |
0 |
% |
|
| ONXX |
Onyx Pharmaceuticals Inc |
EVP & Chief Financial Officer |
• – – |
2013-10-01 |
4 |
D |
$125.00 |
$3,893,750 |
D/D |
(31,150) |
0 |
0 |
- |
|
96 Records found
|
|
Page 4 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
